# OnCo record nct07728019 (trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/trials/nct07728019/>
  a schema:MedicalTrial ;
  onco:kind "trial" ;
  schema:identifier "nct07728019", "NCT07728019" ;
  schema:name "Efficacy and Safety of Retlirafusp Alfa Plus Bevacizumab and Chemotherapy With or Without Short-Course Radiotherapy in Patients With CRCLM"@en ;
  schema:description "A phase 2 trial of bevacizumab (glioblastoma use) and cAPOX (capecitabine, oxaliplatin) in colorectal cancer, run by Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, now recruiting."@en ;
  schema:url <https://onco.cc/trials/nct07728019/> ;
  schema:dateModified "2026-09-24"^^xsd:date ;
  schema:citation <https://clinicaltrials.gov/study/NCT07728019> ;
  onco:status "recruiting" ;
  onco:tag "ctgov-ingest", "colorectal-deep-dive" ;
  onco:phase "2" ;
  onco:cancers <https://onco.cc/cancers/rectal-cancer/>, <https://onco.cc/cancers/colon-cancer/> ;
  onco:technologies <https://onco.cc/technologies/cytotoxic-chemotherapy/>, <https://onco.cc/technologies/imrt-igrt/>, <https://onco.cc/technologies/platinum/> ;
  onco:drugs <https://onco.cc/drugs/bevacizumab-glioma/>, <https://onco.cc/drugs/capox/> ;
  onco:companies <https://onco.cc/companies/hengrui/> .